Stock Financial Ratios, Dividends, Split History

NGL / NGL Energy Partners LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price12.35
Volume1,664,500.00
Market Cap ($M)1,331.92
Enterprise Value ($M)4,228.68
Book Value ($M)2,086.09
Book Value / Share17.16
Price / Book0.67
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 121,568,058
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.03
Balance Sheet (mrq) ($M)
Assets6,151.12
Liabilities4,065.03
Quick Ratio1.11
Current Ratio1.61
Income Statement (mra) ($M)
Equity Method Investment Summarized Financial Information Revenue187,368,000.00
Propane Revenue521,392,000.00
Refined Products And Renewables Revenue12,200,923,000.00
Sales Revenue Net17,282,718,000.00
Oil And Gas Revenue2,260,075,000.00
Water Solutions Revenue229,139,000.00
Liquids Revenue2,070,015,000.00
Other Sales Revenue Net1,174,000.00
Operating Income138.26
Net Income-69.61
Cash Flow Statement (mra) ($M)
Cash From Operations137.64
Cash from Investing270.58
Cash from Financing137.64
Identifiers and Descriptors
CUSIP62913M107
Central Index Key (CIK)1504461
Related CUSIPS
62913M907 62913M957

Split History

Stock splits are used by NGL Energy Partners LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

NGL: Should You Buy This MLP's 13% Yield?

2018-06-14 seekingalpha
Companies with yields this high are generally incredibly risky, with NGL having a very weak balance sheet and much more commodity price exposure than most MLPs.

NGL Energy Partners: The Future's Looking Brighter

2018-06-06 seekingalpha
After months working to change the business for the better, management has finally done that with the recent sale of its Retail Propane operations. (25-1)

NGL Energy Partners: No Distribution Cut, Low Future Capex And Possible Appreciation Of The Stock

2018-06-04 seekingalpha
NGL Energy Partners is a vertically integrated energy company based in Oklahoma that has a fantastic dividend track record.

MLPs: Differentiated Performance

2018-06-03 seekingalpha
Midstream and MLPs synched up this week to rally 2.7%, outperforming the S&P 500 and utilities, despite renewed oil price angst this week. Midstream stocks and MLPs resumed their recovery after last week's pause, and have now posted gains in 7 of the last 10 weeks. After bottoming in late March, the AMZ and AMEI have posted total returns of 16.2% and 12.3%, respectively. The rally has helped the MLP Index break back into positive territory year-to-date, and the MLP Index closed the week almost exactly at its 200-day moving average (269. (62-0)

CANADA STOCKS-TSX futures flat ahead of first-quarter GDP data

2018-05-31 reuters
May 31 (Reuters) - Canada’s main stock index futures was trading flat on Thursday, with investors awaiting the country’s gross domestic product data for the first quarter.

CUSIP: 62913M107